Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy
Top Cited Papers
- 1 January 2013
- Vol. 38 (1), 13-25
- https://doi.org/10.1016/j.immuni.2013.01.004
Abstract
No abstract availableKeywords
This publication has 155 references indexed in Scilit:
- Jakinibs: a new class of kinase inhibitors in cancer and autoimmune diseaseCurrent Opinion in Pharmacology, 2012
- The symphony of the ninth: the development and function of Th9 cellsCurrent Opinion in Immunology, 2012
- Interleukin-2 Inhibits Germinal Center Formation by Limiting T Follicular Helper Cell DifferentiationImmunity, 2012
- Mast Cell Interleukin-2 Production Contributes to Suppression of Chronic Allergic DermatitisImmunity, 2011
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- IL-2 Immunotherapy to Recently HIV-1 Infected Adults Maintains the Numbers of IL-17 Expressing CD4+ T (TH17) Cells in the PeripheryJournal of Clinical Immunology, 2010
- Interleukin-2 and Inflammation Induce Distinct Transcriptional Programs that Promote the Differentiation of Effector Cytolytic T CellsImmunity, 2010
- Decrease of Foxp3+ Treg Cell Number and Acquisition of Effector Cell Phenotype during Lethal InfectionImmunity, 2009
- Janus-Kinase-3-Dependent Signals Induce Chromatin Remodeling at the Ifng Locus during T Helper 1 Cell DifferentiationImmunity, 2008
- Central Role of Defective Interleukin-2 Production in the Triggering of Islet Autoimmune DestructionImmunity, 2008